Hong Kong stock movement | Baoji Pharmaceutical-B (02659.HK) surged over 10% in early trading, recently, the application for the recombinant ustiladine clinical trial was approved by the National Medical Products Administration.

Guosen Securities APP learned that Boji Pharmaceutical-B (02659.HK) surged more than 10% in the morning session, as of the time of publication, it had increased by 5.82% to 19.1 Hong Kong dollars, with a trading volume of 5.3594 million Hong Kong dollars.